InnovaHealth Partners

The firm takes a pure-play healthcare approach, spanning growth equity, expansion capital, and buyouts. It concentrates on medical devices, healthcare services, and digital health platforms, writing checks into companies with clinical validation that need capital and operational support to scale. InnovaHealth also conducts early-stage co-investments alongside specialist healthcare venture funds.

Both. The firm structures control buyouts, typically in the expansion and late-stage segments, while also taking minority co-investment positions alongside healthcare venture managers when an opportunity falls outside its buyout mandate. This dual posture is part of the firm's effort to access deal flow across the full healthcare continuum.

InnovaHealth is exclusively healthcare-focused and does not invest outside the sector. Within healthcare, the firm has not publicly indicated interest in pure biotechnology or early-stage drug discovery, concentrating instead on medical devices, healthcare services, and digital health where regulatory pathways are more established.

The firm's sourcing relies on a network of healthcare executives, clinicians, and former FDA advisors. This operator-led model gives InnovaHealth access to companies that require specialized diligence — particularly around FDA clearance, reimbursement coding, and clinical adoption — that generalist investors rarely build in-house.

No. InnovaHealth Partners is structured as an asset manager, raising capital from external limited partners rather than exclusively managing a single-family's wealth. The firm operates as a sector-specialist private equity manager, not a family office.

InnovaHealth actively co-invests alongside specialist healthcare venture funds when a company's stage or structure does not fit its buyout parameters. This gives the firm early visibility into companies that may later require the growth or buyout capital InnovaHealth can provide directly.

The firm's primary geographic focus is North America, with selected exposure in Western Europe. This aligns with the concentration of FDA-regulated medical device companies and tech-enabled healthcare services platforms that fit the firm's stage and sector criteria.